Compare GSK plc (GSK) vs JBS N.V. Class A Common Shares (JBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JBS N.V. Class A Common Shares — how do they compare? GSK plc trades at $48.84 (market cap $96.45B), while JBS N.V. Class A Common Shares trades at $13.02 (market cap $13.96B). The key difference: GSK plc is far larger — about 6.9× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.31%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and JBS N.V. Class A Common Shares for 0 Days on average.
| GSK | JBS | |
|---|---|---|
Market Cap | $96.45B | $13.96B |
Volume | 7,087,457 | 5,326,589 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $18.42 |
52-Week Low | $43.24 | $10.86 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $116.51B | $34.93B |
Dividend Yield | 3.79% | 10.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by three consecutive quarterly earnings beats. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology growth targeting £40B in sales. Cash flow trends show consistent operational strength with $7.7B from operations in 2025.
GSK presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 14.84 P/E ratio and dividend yield, but faces headwinds from HIV patent expirations and bearish technical indicators. Analyst consensus leans cautious with 55% hold ratings, suggesting patience may be warranted despite the company's solid operational performance.
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →
